Memorial Sloan Kettering Cancer Center (MSK) is a free-standing NCI-designated Comprehensive Cancer Center dedicated to improving the standards of cancer treatment, prevention and control. MSK?s research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Structural and Chemical Biology); Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences); and Patient-Oriented Research (Clinical Research and Population Science Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators. MSK seeks to encourage the application of scientific discoveries in a way that advances the prevention, detection, diagnosis, and treatment of the many forms of cancer that are relevant to the population in our catchment area. Scientific work in the 10 research programs depends on services provided by 26 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 20 of these core facilities. Over the next five years, MSK will continue to enhance its clinical and research facilities and its research and training programs in emerging research areas. Support is requested to provide developmental funding for the support of newly recruited investigators in computational biology, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.

Public Health Relevance

Memorial Sloan Kettering Cancer Center (MSK) is a free-standing institution dedicated to the control of cancer through inpatient and outpatient care, clinical and research training programs, and a broad spectrum of research activities. Through these activities, MSK seeks to reduce the burden of cancer throughout our catchment area and the nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-53S1
Application #
9921714
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2019-02-01
Budget End
2019-12-31
Support Year
53
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386
Assel, Melissa J; Gerdtsson, Axel; Thorek, Daniel L J et al. (2018) Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project. Oncotarget 9:5778-5785
Katsoulakis, Evangelia; Leeman, Jonathan E; Lok, Benjamin H et al. (2018) Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery. Laryngoscope 128:2539-2545
Breitbart, William (2018) In Memoriam: Jimmie C. Holland, MD, 1928-2017. Palliat Support Care 16:124-126
Hoseini, Sayed Shahabuddin; Guo, Hongfen; Wu, Zhihao et al. (2018) A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv 2:1250-1258
Grkovski, Milan; Fanchon, Louise; Pillarsetty, Naga Vara Kishore et al. (2018) 18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model. EJNMMI Res 8:53
Tollinche, Luis; Tan, KaySee; Han, Austin et al. (2018) Analyzing Volatile Anesthetic Consumption by Auditing Fresh Gas Flow: An Observational Study at an Academic Hospital. Int J Anesth Anesth 5:
Lin, Ching-Jung; Hu, Fuqu; Dubruille, Raphaelle et al. (2018) The hpRNA/RNAi Pathway Is Essential to Resolve Intragenomic Conflict in the Drosophila Male Germline. Dev Cell 46:316-326.e5
Tadros, Audree B; Wen, Hannah Y; Morrow, Monica (2018) Breast Cancers of Special Histologic Subtypes Are Biologically Diverse. Ann Surg Oncol 25:3158-3164
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158

Showing the most recent 10 out of 8799 publications